52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Moderna Announces The European Commission's Approval Of Advance Purchase Agreement For Initial 80 Million Doses Of COVID-19 Vaccine
Moderna’S Covid-19 Vaccine Candidate Meets Its Primary Efficacy Endpoint In The First Interim Analysis Of The Phase 3 Cove Study
Moderna Has Completed Case Accrual For First Planned Interim Analysis Of Its Vaccine Against Covid-19
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
Biotechnology & Drugs
200 Technology Sq
Noubar B. Afeyan
Non-Executive Independent Chairman of the Board, Co-Founder
Chief Executive Officer, Director
David W. Meline
Chief Financial Officer
Chief Human Resource Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Pfizer Inc with partner BioNTech SE and Moderna Inc have released trial data showing their COVID-19 vaccines to be about 95% effective at preventing the illness, while AstraZeneca Plc this week said its vaccine could be up to 90% effective.
Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc have released trial data this month showing their experimental vaccines are effective in preventing the disease. If regulators approve any of the vaccines in coming weeks, the companies have said distribution...
Countries around the world agonised over new coronavirus curbs ahead of Christmas and other holidays as global infections crossed 60 million and U.S. officials pleaded with Americans to stay home over Thanksgiving.
Sweden's Recipharm will produce doses of Moderna's COVID-19 vaccine candidate in central France, the company said on Wednesday, adding it had started recruiting and investing to start manufacturing.
The European Union has struck a deal for up to 160 million doses of U.S. firm Moderna's COVID-19 vaccine candidate, the head of the European Commission said on Tuesday, taking the EU's potential stock of COVID-19 shots to nearly 2 billion.
The European Union has reached a deal with U.S. biotech firm Moderna for the supply of up to 160 million doses of its COVID-19 vaccine candidate, the president of the European Commission said on Tuesday.
The European Medicines Agency (EMA) could produce a scientific opinion on COVID-19 vaccines seeking regulatory approval by the end of the year in a best case scenario, the regulator's new chief was quoted as saying on Tuesday.
Swedish pharmaceuticals maker Recipharm said on Tuesday it had agreed a preliminary deal with Moderna Inc to fill and seal the packaging for the U.S drugmaker's new COVID-19 vaccine.
Britain is on track to make COVID-19 vaccines widely available by next spring after the shot developed by Oxford University and AstraZeneca was up to 90% effective in trials, the head of the university's Jenner Institute told Reuters on Monday.
The experimental COVID-19 vaccine developed by AstraZeneca and Oxford University would have a higher efficacy rate if trials were only measuring whether the shot prevents hospitalisation and severe disease, Oxford's vaccine chief said on Monday.
Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).
A number of hedge funds sold positions in two drug companies leading the race to a coronavirus vaccine in the quarter before both announced breakthroughs that lifted their stock prices, while a few took stakes in the companies during that time.
COVID-19 vaccines from Pfizer Inc and Moderna Inc could be ready for U.S. authorization and distribution within weeks, setting the stage for inoculation to begin as soon as this year, U.S. Health and Human Services Secretary Alex Azar said on Wednesday.
Pfizer Inc's and Moderna Inc's COVID-19 vaccine candidates could be ready for U.S. authorization and distribution within weeks, setting the stage for widespread inoculation to begin as soon as this year, U.S. Health and Human Services Secretary Alex Azar said during a press...
Air France-KLM is among airlines gearing up for the challenge of transporting millions of doses of temperature-sensitive COVID-19 vaccines in the midst of a travel slump.
(This Nov. 16 story corrects spelling and location of 6 Meridian)
Airlines are scrambling to prepare ultra-cold shipping and storage facilities to transport COVID-19 vaccines developed by Pfizer and Moderna, whose doses, which require deep freezing, are likely to be among the first to be distributed.
Hong Kong stocks ended higher for a third straight session on Wednesday, with the automotive sector leading gains, as investors continued to cheer news of COVID-19 vaccine breakthroughs.
Indian shares were little changed on Wednesday as investors locked in gains after a record-setting rally, and surging coronavirus cases globally took the focus away from upbeat vaccine trial results.
A gauge of global stocks edged lower from a record on Tuesday, as rising coronavirus cases raised concerns about fresh lockdown measures and tamped down recent optimism over promising vaccine trial results.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.